Sygnature Discovery has recently announced a state-of-the-art Early Candidate Developability Screening Group located in Nottingham, UK. By bridging into formal preclinical drug development and paving the way for clinical trials, the new service line will expand on the company’s offerings to customers.
The brand-new world-class business and facility unit will be working in September 2021 and has had over one million pounds of capital investment already committed. Furthermore, the business and facility unit is being set up to work alongside the parallel in vitro and in vivo pharmacology, chemistry and DMPK capabilities.
“Sygnature Discovery has recently announced a state-of-the-art Early Candidate Developability Screening Group.“
Sygnature Discovery will create effective growth strategies suited to the attributes of each API and will quickly and unbiasedly define the most phase-appropriate development approach to overcome even the most complicated bioavailability obstacles, thanks to access to well-equipped pre-formulation and formulation development laboratories.
SVP of Pre-Clinical Development, Dr Richard Weaver, stated: “There is an increasing need for engaging the formulation scientist at an earlier stage and most importantly having constant and iterative dialogue with the DMPK, Pharmacology and Chemistry teams. Inadequate bioavailability in many late-stage research and development compounds is a real modern day challenge. There is often a way forward if the reasons for the poor bioavailability are not due to DMPK reasons. A key part of this process is making the human efficacious dose prediction range as early as possible and feeding this information to the formulating scientists, along with the theoretical gains that can be made”.
Previous founder and CEO of Kuecept, Dr Mark Saunders, stated: “I am delighted to be working with the team at Sygnature Discovery to help build this new capability. Already we have been able to attract leading scientific talent to drive this initiative and I am confident of the advice and experimental capability that we will be able to give to clients to help get much needed new medicines on the market with minimal hurdles and the maximal chance of the achieving right drug exposure to fit the need.”
Chief Operating Officer, Dr Paul Overton, stated: “Our expansion of the value chain into early CMC development will be of significant benefit to our customers as we partner with them from early drug discovery. The expansion into the formulation space fits with our strategic goal of being able to have the line of sight of the clinic and feeding this into our earliest discussions with the customer to maximise their chance of clinical success”.